Fig. 2
SW IV-134 sensitizes pancreatic cancer cells to gemcitabine. a BxPC-3, b AsPC-1, c CFPAC-1, d MIA PaCa-2, and e PANC-1 cells were treated with SW IV-134 (1 μM), gemcitabine (0.5 μM), or in combination with the two drugs using the same concentrations. Titer-Glo viability assays were performed after 3 - 4 days post treatment (MIA PaCa-2, 4 days; all other cell lines, 3 days). The data were normalized to DMSO treated control cells (***p < 0.001) (n = 3)